Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc
On January 2, 2024, Bailey John E. (Jack) Jr., the President and CEO of G1 Therapeutics Inc (NASDAQ:GTHX), executed a sale of 32,983 shares of the company. The transaction was filed with the SEC and can be found in detail within the provided SEC Filing.
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative therapies that improve the lives of those affected by cancer. The company's research and development efforts are centered on small molecule therapies that have the potential to address significant unmet needs in the treatment of cancer.
Over the past year, the insider has sold a total of 73,328 shares and has not made any purchases of the company's stock. This latest sale continues a trend of insider selling activity at G1 Therapeutics Inc, with a total of 13 insider sells and no insider buys occurring over the past year.
On the date of the insider's recent sale, shares of G1 Therapeutics Inc were trading at $3.27, resulting in a market capitalization of $150.865 million for the company.
The stock's price of $3.27 compared to the GuruFocus Value of $14.40 indicates a price-to-GF-Value ratio of 0.23. According to this metric, G1 Therapeutics Inc is categorized as a Possible Value Trap, and investors are advised to think twice before making an investment based on its GF Value.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated using historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling activity at G1 Therapeutics Inc.
The GF Value image provides a visual representation of the stock's current price relative to its intrinsic value according to GuruFocus estimates.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
